Novo Nordisk A/S NVO
40.31 USD +0.01 (+0.02%)
At closeNov 6, 2026, 7:58 PM EST
40.34 +0.03 +0.08%
After hours · Nov 6, 7:58 PM ET
39.53 Day range 40.55
35.29 52-week range 63.98
- YTD
- -20.77%
- 1 year
- -13.33%
Analyst view
Price target (mean) 44.88 +11.3% upside
Now 40.31
- Target (low)
- 39.56
- Target (mean)
- 44.88
- Target (high)
- 61.50
Ratings (0m) 14 3 buy · 10 hold · 1 sell
- Strong buy0
- Buy3
- Hold10
- Sell1
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 4.31 | 4.26 – 4.36 | 6.04 | -28.7% | 77.27B | -2.4% | 2 |
| Next quarter | 5.80 | 5.80 – 5.80 | 6.63 | -12.5% | 73.00B | +4.2% | 1 |
| Current year | 22.39 | 21.01 – 24.25 | 23.03 | -2.8% | 304.96B | -1.3% | 8 |
| Next year | 22.89 | 21.73 – 23.74 | 22.39 | +2.3% | 309.95B | +1.6% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | BMO Capital | Maintained | Market Perform | Market Perform |
| Sep 11, 2026 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Mar 2, 2026 | Goldman Sachs | Downgrade | Buy | Neutral |
| Feb 24, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Jan 9, 2026 | CICC | Initiated | — | Outperform |
| Dec 8, 2025 | Argus Research | Downgrade | Buy | Hold |
| Nov 28, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Nov 25, 2025 | BMO Capital | Maintained | Market Perform | Market Perform |
| Nov 24, 2025 | HSBC | Downgrade | Buy | Hold |
| Oct 14, 2025 | BMO Capital | Maintained | Market Perform | Market Perform |
| Oct 2, 2025 | HSBC | Upgrade | Hold | Buy |
| Sep 29, 2025 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Sep 17, 2025 | Berenberg | Upgrade | Hold | Buy |
| Aug 19, 2025 | TD Cowen | Maintained | Buy | Buy |
| Aug 5, 2025 | UBS | Downgrade | Buy | Neutral |
| Jul 31, 2025 | HSBC | Downgrade | Buy | Hold |
| Jul 30, 2025 | Barclays | Downgrade | Overweight | Equal-Weight |
| Jun 18, 2025 | TD Cowen | Reiterated | Buy | Buy |
| Apr 17, 2025 | BMO Capital | Downgrade | Outperform | Market Perform |
| Jan 8, 2025 | UBS | Upgrade | Sell | Buy |
| Dec 23, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 6, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Oct 22, 2024 | Citigroup | Maintained | Buy | Buy |
| Oct 17, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Oct 16, 2024 | Barclays | Maintained | Overweight | Overweight |
| Oct 14, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| Oct 10, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Oct 10, 2024 | Jefferies | Initiated | — | Buy |
| Sep 20, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 16, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
